Michael E. Williams

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Peter McLaughlin, A.J. Grillo-López, Brian K. Link et al. · Journal of Clinical Oncology · 1998 · 2.8K citations

Pharmacy, Hematology, Immunology +17

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

S. Vincent Rajkumar, Susanna Jacobus, Natalie S. Callander et al. · The Lancet Oncology · 2009 · 933 citations · Full text

Medicine, Hematology, Oncology +11

Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma

Katherine Robinson, Michael E. Williams, Richard H. van der Jagt et al. · Journal of Clinical Oncology · 2008 · 352 citations

Medicine, Pharmacology, Pharmacotherapy +13

Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study

André Goy, Rajni Sinha, Michael E. Williams et al. · Journal of Clinical Oncology · 2013 · 349 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study

Jonathan W. Friedberg, Philip Cohen, Ling Chen et al. · Journal of Clinical Oncology · 2008 · 298 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15